$TLRY

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

Original reporting
Published Oct 29, 2026, 5:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TLRY
Bullish
high confidence
Mentioned
$TLRY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TLRYBullishMed
01

Why it matters

The analyst's price target raise provides a fresh catalyst that could drive short‑term buying pressure.

02

Market read

Analyst upgrade on Tilray may influence the cannabis sector and related beverage stocks.

03

What to watch

Potential regulatory risks in the cannabis sector and execution risk of the brewing consolidation.

Relevance 7/10Novelty 7/10Timing: today

Background

Tilray Brands is a cannabis and beverage company undergoing a brewing unit consolidation to cut costs and add Carlsberg volume.

Company-level read

Ticker impact

$TLRYBullishHigh confidence
Context

Jefferies raised its price target on Tilray to $13, citing the brewing restructuring and expected cost savings.

Expected impact

likely upward pressure as investors price in the improved outlook.

Evidence & confidence

The new target reflects concrete operational savings and volume growth, providing a clear catalyst for a short‑term rally.

Market effects

The restructuring may set a benchmark for cost‑cutting in the cannabis‑beverage niche.

U.S. cannabis stocks could see modest gains as Tilray's outlook improves.

Limited to investors focused on Tilray and related beverage partnerships.

Counterpoint

The price target increase may be premature given Tilray's ongoing losses and market volatility.

Key entities

  • Tilray Brands Inc.

    Cannabis and beverage firm undergoing restructuring.

  • Jefferies

    Raised price target and maintained Reduce rating.

Related articles

$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

$TLRYMed

Tilray Brands revenue rises 20% in Q1 2027

Tilray Brands reported a 20% revenue increase to $257.1M in Q1 2027, driven by beverage sales. Gross profit rose 35% to $77.5M. Beverage revenue grew 82% to $101.5M, while cannabis revenue declined. The company reported a net loss of $40M but reduced debt by $42M. Tilray reaffirmed its adjusted EBITDA guidance of $68M-$75M for the fiscal year.